Disc Medicine, Inc.

Disc Medicine, Inc., trading under the SPAC ticker FSDC, filed an 8-K with the SEC on December 28, 2022, under accession number 0001140361-22-047153. The vehicle is associated with Foresite Capital Acquisition Corp. IV, sponsored by Foresite Capital Management, a healthcare-focused investment firm. The SPAC completed its initial public offering in 2021 and targeted opportunities in the life sciences and biopharmaceutical sector, with a particular emphasis on hematology. Disc Medicine focuses on the development of treatments for serious blood disorders. As of the filing date the de-SPAC transaction process was underway. For complete filing details, capital structure data, and timeline analytics on FSDC, sign up for full access at SpacDesk.